Covalent Modifiers

FEBRUARY 1, 2024

Science 383 , eadi5798 (2024). Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers. Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers. Skye Montoya et al.

Targeted Protein Degradation 173

Targeted Protein Degradation Clinical Trials Trials Science 173

BMG Labtech

MAY 22, 2024

Options for cell-based protein degrader assays Interest is growing in the use of targeted-protein degradation to induce the breakdown of disease-causing proteins after treatment with small molecule drugs.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Treatment Disease 52

Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. UBE Corporation: www.ube.com

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Drug Target Review

JULY 23, 2024

I studied Natural Sciences at the University of Cambridge, where I was exposed to a range of disciplines from chemistry to physiology, specialising in my last year in biochemistry. Pushing the boundaries of science always opens the door to new, impactful developments, although there are always challenges along the way.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Despite advancements in oncology in recent years, considerable unmet need persists in the treatment of HR+ breast cancer.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Science Small Molecule 52